Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Onxeo

Onxeo
1997 FOUNDED
PUBLIC STATUS
41-50 EMPLOYEES
ONXEO STOCK SYMBOL
2 INVESTMENTS
$0.58 SHARE PRICE (As of Friday Closing)
Description

Onxeo SA is a biotechnology company that is engaged in developing oncology drugs based on tumor DNA targeting. The company focuses on developing disruptive compounds from preclinical research. It produces and develops orphan oncology products under the brand names Livatag, Validive, Beleodaq, platON and AsiDNA.

Website
Formerly Known As
Topotarget, BioAlliance Pharma
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
PAR
Primary Office
  • 49 Boulevard du General
  • Martial Valin
  • 75015 Paris
  • France

+33 01 00 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Onxeo’s full profile, request a free trial.

Onxeo Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.55 - $1.20 $32.4M $0.59 -$0.18 121K 55.4M

Onxeo Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 35,285 37,902 33,704 87,796
Revenue 6,534 7,230 10,719 4,894
EBITDA (7,441) (1,526) (29,461) (23,899)
Net Income (10,350) (11,091) (66,618) (25,077)
Total Assets 67,053 72,352 93,664 131,568
Total Debt 1,554 515 156 111
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Onxeo Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Onxeo‘s full profile, request access.

Request full access to PitchBook

Onxeo Competitors (64)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
FORMA Therapeutics Venture Capital-Backed Watertown, MA 000 00000 000000000 00000
000000000 Corporation Illkirch-Graffenstaden, France 000 00000 000000000 00000
00000000 Formerly VC-backed South San Francisco, CA 00 00000 0000000000.
00000000 00000000 Corporate Backed or Acquired Boston, MA 0 00.000 000000000 00.000
000000000(00000000 Formerly VC-backed New York, NY 000 00000 000000 - 000 00000
To view this company’s complete list of competitors, request access »

Onxeo Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000000 25-Mar-2016 000000000000000000 00.000 Drug Discovery 000000 0000000 00.0
Topotarget 05-Aug-2014 Merger/Acquisition 00000 Drug Discovery
To view this company’s complete investment and acquisition history, request access »

Onxeo Subsidiaries (1)

Company Name Industry Location Founded
0000000000 Drug Discovery Copenhagen, Denmark 0000
To view this company’s complete subsidiary history, request access »

Onxeo Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Onxeo‘s full profile, request access.

Request full access to PitchBook

Onxeo Executive Team (7)

Name Title Board
Seat
Contact
Info
Judith Greciet Ph.D Chief Executive Officer and Board Member
Nicolas Fellmann Chief Financial Officer & Secretary to the Board of Directors
Françoise Bono Chief Scientific Officer
Michel Forest Chief Pharmacist and Quality Assurance Director
Olivier De Beaumont Chief Medical Officer

2 Former Executives

You’re viewing 5 of 7 executives. Get the full list »

Onxeo Board Members (15)

Name Representing Role Since Contact
Info
00000 000000 00.0 Self Member, Supervisory Board 000 0000
0000è00 00000 00000000 Self Independent Director 000 0000
00000 0000000 00.0 Self Independent Director 000 0000
0000-00000 00000000 Self Chairman, Supervisory Board 000 0000
0000-000000 0000000 00 Self Board Member 000 0000

4 Former Board Members

You’re viewing 5 of 15 board members. Get the full list »